Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Still a Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped up before the market opened on Monday . The stock had previously closed at $8.54, but opened at $9.05. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.81, with a volume of 3,202 shares traded.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 3.7%

The business has a 50 day moving average of $8.38 and a two-hundred day moving average of $8.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.74 and a current ratio of 6.44. The stock has a market capitalization of $14.97 billion, a PE ratio of 13.75, a PEG ratio of 2.00 and a beta of 0.19.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its earnings results on Monday, October 27th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 39.53% and a return on equity of 11.90%. The company had revenue of $740.85 million during the quarter, compared to the consensus estimate of $742.35 million. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.